Ki-67 Expression in megakaryocytes: A new prognostic marker in Myelodysplastic Syndromes
A new bone marrow marker predicts which myelodysplasia patients will progress faster, using cells already examined during standard biopsy.
Evaluation of Ki-67 expression in megakaryocytes from MDS patient bone marrow samples revealed that elevated proliferation index independently predicts prognosis beyond current IPSS-R scoring. This novel pathology-based biomarker is assessable from routine bone marrow biopsies, offering immediate clinical applicability for MDS risk stratification.
What the study was
- Study design
- retrospective_cohort
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Virchows Archiv
Why it surfaced
Novel discovery of a megakaryocyte-specific prognostic biomarker in MDS—a malignancy with significant unmet need for improved risk tools. Virchows Arch is a leading pathology journal. Direct T1 core hit.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.